| Literature DB >> 33619633 |
Christopher X W Tan1, Henk S Brand2, Bilgin Kalender2, Nanne K H De Boer3, Tymour Forouzanfar4, Jan G A M de Visscher4.
Abstract
OBJECTIVES: Although bowel symptoms are often predominant, inflammatory bowel disease (IBD) patients can have several oral manifestations. The aim of this study was to investigate the prevalence of dental caries and periodontal disease in patients with Crohn's disease (CD) and ulcerative colitis (UC) compared to an age and gender-matched control group of patients without IBD.Entities:
Keywords: Crohn’s disease; DMFT (Decayed; DPSI (Dutch Periodontal Screening Index); Filled Teeth); Inflammatory bowel disease; Missing; Oral health; Ulcerative colitis
Mesh:
Year: 2021 PMID: 33619633 PMCID: PMC8370899 DOI: 10.1007/s00784-021-03835-6
Source DB: PubMed Journal: Clin Oral Investig ISSN: 1432-6981 Impact factor: 3.573
The Dutch Periodontal Screening Index scoring system
| DPSI | |
|---|---|
| 0 | - Probing depth ≤ 3mm - No bleeding on probing - No dental tartar - No overhanging restorations |
| 1 | Same as 0, but bleeding on probing |
| 2 | Same as 1, but with dental tartar and/or overhanging restorations |
| 3− | Probing depth of 4-5 mm without gingival recession |
| 3+ | Probing depth of 4-5 mm with gingival recession |
| 4 | Probing depth ≥ 6mm |
|
| Edentulous |
1st sextant: right upper (pre)molar region, 2nd sextant: upper front region, 3rd sextant: left upper (pre)molar region, 4th sextant: left lower (pre)molar region, 5th sextant: lower front region, 6th sextant: right lower (pre)molar region
List of medication used in treatment of inflammatory bowel disease in the Netherlands
| Corticosteroids | Biologicals | Immunosuppressants | Aminosalicylates |
|---|---|---|---|
| Beclometasone | Adalimumab | Azathioprine | Mesalazine |
| Betamethasone | Golimumab | Mercaptopurine | Olsalazine |
| Budesonide | Infliximab | Tioguanine | Sulfasalazine |
| Dexamethasone | Vedolizumab | Methotrexate | Salazopyrine |
| Methylprednisolone | Ustekinumab | Tacrolimus | |
| Prednisolone | Ciclosporine | ||
| Prednisone | |||
| Triamcinolone | |||
| Triamcinolonacetonide | |||
| Hydrocortisone | |||
| Cortiment | |||
| Entocort |
Demographic characteristics of IBD patients (n = 229) and non-IBD controls (n = 229)
| IBD | Non-IBD | ||
|---|---|---|---|
| Male | 96 | 96 | |
| Female | 133 | 133 | |
| Mean age (years) | 51 ± 16 | 51 ± 16 | |
| Crohn’s disease | |||
| Male | 60 | ||
| Female | 88 | ||
| Total | 148 | ||
| Ulcerative colitis | |||
| Male | 36 | ||
| Female | 44 | ||
| Total | 80 | ||
| IBD undetermined | 1 | ||
| Diabetes mellitus | 15 | 15 | |
| Smoking | 53 | 72 | 0.046 |
| Daily intake of alcohol | 19 | 17 | 0.728 |
| Use of IBD-related medication | 125 | 4 | <0.0005 |
Total DMFT indices of IBD patients (n = 212) and controls (n = 212), stratified for all and 4 oral regions. DMFT data are presented as mean ± SD
| IBD | Non-IBD | ||
|---|---|---|---|
| DMFT total | 14.3 ± 7.8 | 12.3 ± 7.0 | 0.012 |
| DMFT upper front region | 2.5 ± 2.4 | 1.9 ± 2.3 | 0.013 |
| DMFT upper (pre)molar region | 5.6 ± 2.6 | 5.3 ± 2.6 | 0.135 |
| DMFT lower front region | 1.0 ± 1.9 | 0.5 ± 1.3 | <0.0005 |
| DMFT lower (pre)molar region | 5.2 ± 2.4 | 4.7 ± 2.5 | 0.023 |
DMFT indices of CD patients (n = 135) and controls (n = 135), stratified for all and 4 oral regions. DMFT data are presented as mean ± SD
| DMFT | CD | Non-IBD | |
|---|---|---|---|
| DMFT total | 14.6 ± 8.0 | 11.8 ± 7.1 | 0.002 |
| DMFT upper front region | 2.6 ± 2.5 | 1.8 ± 2.2 | 0.004 |
| DMFT upper (pre)molar region | 5.7 ± 2.7 | 5.1 ± 2.7 | 0.076 |
| DMFT lower front region | 1.1 ± 1.9 | 0.4 ± 1.3 | 0.001 |
| DMFT lower (pre)molar region | 5.3 ± 2.5 | 4.5 ± 2.5 | 0.016 |
DMFT indices of UC patients (n = 76) and controls (n = 76), stratified for all and 4 oral regions. DMFT data are presented as mean ± SD
| DMFT | UC | Non-IBD | |
|---|---|---|---|
| DMFT total | 13.8 ± 7.5 | 13.2 ± 6.8 | 0.643 |
| DMFT upper front region | 2.2 ± 2.4 | 2.0 ± 2.3 | 0.628 |
| DMFT upper (pre)molar region | 5.5 ± 2.6 | 5.6 ± 2.4 | 0.748 |
| DMFT lower front region | 0.9 ± 1.8 | 0.6 ± 1.4 | 0.287 |
| DMFT lower (pre)molar region | 5.2 ± 2.4 | 4.9 ± 2.4 | 0.591 |
DPSI scores of IBD patients (n = 211) compared to the control group (n = 211). DPSI scores 0, 1, and 2 were combined because these categories indicate no clinical attachment loss. The DPSI scores and the percentage of edentulism in each sextant were compared using Chi-square tests
| DPSI | ≤ 2 | 3− | 3+ | 4 | Edentulous | ||
|---|---|---|---|---|---|---|---|
| 1st sextant control | 83 (39%) | 61 (29%) | 17 (8%) | 34 (16%) | 0.539 | 16 (8%) | 0.040 |
| 1st sextant IBD | 78 (37%) | 50 (24%) | 11 (5%) | 43 (20%) | 29 (14%) | ||
| 2nd sextant control | 137 (65%) | 39 (19%) | 15 (7%) | 11 (5%) | 0.409 | 9 (4%) | 0.003 |
| 2nd sextant IBD | 129 (61%) | 32 (15%) | 8 (4%) | 16 (8%) | 26 (12%) | ||
| 3rd sextant control | 88 (42%) | 59 (28%) | 18 (9%) | 32 (15%) | 0.955 | 14 (7%) | 0.016 |
| 3rd sextant IBD | 79 (37%) | 61 (29%) | 16 (8%) | 26 (12%) | 29 (14%) | ||
| 4th sextant control | 100 (47%) | 60 (28%) | 15 (7%) | 31 (15%) | 0.664 | 5 (2%) | 0.001 |
| 4th sextant IBD | 82 (39%) | 64 (30%) | 19 (9%) | 24 (11%) | 22 (10%) | ||
| 5th sextant control | 166 (79%) | 18 (9%) | 12 (6%) | 12 (6%) | 0.087 | 3 (1%) | 0.018 |
| 5th sextant IBD | 155 (74%) | 25 (12%) | 5 (2%) | 14 (7%) | 12 (6%) | ||
| 6th sextant control | 103 (48%) | 55 (26%) | 13 (6%) | 35 (17%) | 0.574 | 5 (2%) | 0.005 |
| 6th sextant IBD | 90 (43%) | 62 (29%) | 14 (7%) | 27 (13%) | 18 (9%) |
DPSI scores of CD patients (n = 136) compared to the control group (n = 136). DPSI scores 0, 1, and 2 were combined because these categories indicate no clinical attachment loss. The DPSI scores and the percentage of edentulism in each sextant was compared using Chi-square tests
| DPSI | ≤ 2 | 3− | 3+ | 4 | Edentulous | ||
|---|---|---|---|---|---|---|---|
| 1st sextant control | 57 (42%) | 43 (32%) | 9 (7%) | 19 (14%) | 0.903 | 8 (6%) | 0.017 |
| 1st sextant CD | 48 (35%) | 36 (27%) | 8 (6%) | 24 (18%) | 20 (15%) | ||
| 2nd sextant control | 90 (66%) | 27 (20%) | 8 (6%) | 6 (4%) | 0.578 | 5 (4%) | 0.008 |
| 2nd sextant CD | 80 (59%) | 22 (16%) | 7 (5%) | 10 (7%) | 17 (13%) | ||
| 3rd sextant control | 59 (43%) | 42 (31%) | 10 (7%) | 18 (13%) | 0.754 | 7 (5%) | 0.013 |
| 3rd sextant CD | 48 (35%) | 41 (30%) | 11 (8%) | 17 (13%) | 19 (14%) | ||
| 4th sextant control | 65 (48%) | 43 (32%) | 6 (4%) | 19 (14%) | 0.125 | 3 (2%) | 0.003 |
| 4th sextant CD | 52 (38%) | 43 (32%) | 15 (11%) | 11 (8%) | 15 (11%) | ||
| 5th sextant control | 110 (81%) | 13 (10%) | 5 (4%) | 6 (4%) | 0.522 | 2 (2%) | 0.053 |
| 5th sextant CD | 101 (74%) | 15 (11%) | 4 (3%) | 8 (6%) | 8 (6%) | ||
| 6th sextant control | 63 (46%) | 42 (31%) | 11 (8%) | 17 (13%) | 0.817 | 3 (2%) | 0.028 |
| 6th sextant CD | 58 (43%) | 44 (32%) | 10 (7%) | 13 (10%) | 11 (8%) |
DPSI scores of UC patients (n = 74) compared to the control group (n = 74). DPSI scores 0, 1, and 2 were combined because these categories indicate no clinical attachment loss. The DPSI scores and the percentage of edentulism in each sextant was compared using Chi-square tests
| DPSI | ≤ 2 | 3− | 3+ | 4 | Edentulous | ||
|---|---|---|---|---|---|---|---|
| 1st sextant control | 25 (34%) | 18 (24%) | 8 (11%) | 15 (20%) | 0.245 | 8 (11%) | 0.797 |
| 1st sextant UC | 30 (41%) | 14 (19%) | 2 (3%) | 19 (26%) | 9 (12%) | ||
| 2nd sextant control | 46 (62%) | 12 (16%) | 7 (10%) | 5 (7%) | 0.398 | 4 (5%) | 0.147 |
| 2nd sextant UC | 48 (65%) | 10 (14%) | 1 (1%) | 6 (8%) | 9 (12%) | ||
| 3rd sextant control | 29 (39%) | 16 (22%) | 8 (11%) | 14 (19%) | 0.659 | 7 (10%) | 0.439 |
| 3rd sextant UC | 30 (41%) | 20 (27%) | 5 (7%) | 9 (12%) | 10 (14%) | ||
| 4th sextant control | 35 (47%) | 16 (22%) | 9 (12%) | 12 (16%) | 0.492 | 2 (3%) | 0.085 |
| 4th sextant UC | 29 (39%) | 21 (28%) | 4 (5%) | 13 (18%) | 7 (10%) | ||
| 5th sextant control | 55 (74%) | 5 (7%) | 7 (10%) | 6 (8%) | 0.149 | 1 (1%) | 0.172 |
| 5th sextant UC | 53 (72%) | 10 (14%) | 1 (1%) | 6 (8%) | 4 (5%) | ||
| 6th sextant control | 39 (53%) | 13 (18%) | 2 (3%) | 18 (24%) | 0.511 | 2 (3%) | 0.085 |
| 6th sextant UC | 31 (42%) | 18 (24%) | 4 (5%) | 14 (19%) | 7 (10%) |